AP
ONC

Advisors Preferred’s BeOne Medicines Ltd ONC Stock Holding History

Advisors Preferred’s Portfolio ONC Stock Details ONC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q2 		– Sell
-534
Closed -$145K – 308
2025
Q1 		$145K Buy
+534
New +$125K 0.02% 209
2018
Q1 		– Sell
-961
Closed -$94K – 305
2017
Q4 		$94K Buy
+961
New +$88K 0.04% 138

Other funds holding ONC

BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $169B AUM 114.72% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $484B AUM 34.9% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $832M AUM 32.38% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $4.94B AUM 244.43% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Advisors Preferred's ONC Position: Q2 2025 in Review

Advisors Preferred sold out of BeOne Medicines Ltd (ONC) in Q2 2025, closing a stake of 534 shares — an estimated $145K sold.

Advisors Preferred first reported a position in ONC in Q4 2017 and held it in 2 quarters. The position peaked at $145K in Q1 2025. 244 funds tracked by Wall St. Rank hold ONC as of Q2 2025.

  • Advisors Preferred reported no remaining BeOne Medicines Ltd position as of Q2 2025 after selling out during the quarter.
  • Advisors Preferred sold 534 BeOne Medicines Ltd shares in Q2 2025, an estimated $145K.
  • Advisors Preferred first reported a position in BeOne Medicines Ltd in Q4 2017 and held it in 2 quarters.
  • Advisors Preferred's BeOne Medicines Ltd position peaked at $145K in Q1 2025.
  • 244 funds tracked by Wall St. Rank held BeOne Medicines Ltd as of Q2 2025.

Based on Advisors Preferred's 13F filing for Q2 2025, filed 5 Aug 2025.